share_log

AbbVie | 10-Q: Q2 2024 Earnings Report

AbbVie | 10-Q: Q2 2024 Earnings Report

艾伯維公司 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/08 03:01

Moomoo AI 已提取核心訊息

AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
艾伯維公司報告2024年第二季度全球淨收入爲145億美金，同比增長4.3%，營業收入爲40億美金，攤薄後每股收益爲0.77美金。增長主要得益於Skyrizi和Rinvoq，二者的收入分別激增44.8%和55.8%，幫助抵消了因生物相似藥競爭而導致的Humira銷售下降29.8%。該公司於2024年2月完成了對ImmunoGen的98億美金收購，增強了其腫瘤學產品組合，其中Elahere在第二季度產生了12800萬美金的收入。艾伯維公司發行了150億美金的高級票據，以融資ImmunoGen和Cerevel Therapeutics的收購。毛利率從2023年第二季度的69%提升至71%，受益於無形...展開全部
艾伯維公司報告2024年第二季度全球淨收入爲145億美金，同比增長4.3%，營業收入爲40億美金，攤薄後每股收益爲0.77美金。增長主要得益於Skyrizi和Rinvoq，二者的收入分別激增44.8%和55.8%，幫助抵消了因生物相似藥競爭而導致的Humira銷售下降29.8%。該公司於2024年2月完成了對ImmunoGen的98億美金收購，增強了其腫瘤學產品組合，其中Elahere在第二季度產生了12800萬美金的收入。艾伯維公司發行了150億美金的高級票據，以融資ImmunoGen和Cerevel Therapeutics的收購。毛利率從2023年第二季度的69%提升至71%，受益於無形資產的攤銷減少。研發費用增加12%，達到19億美金，因爲艾伯維公司繼續投資其研發管道。該公司將季度股息維持在每股1.55美金，並在2024年上半年回購了500萬股，耗資95900萬美金。2024年第二季度的有效稅率爲36%，較2023年第二季度的22%有所上升，主要是由於業務開發活動。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。